LC
KNTE

Lindbrook Capital’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Lindbrook Capital’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,068
Closed -$13K – 3051
2022
Q3 		$13K Buy
1,068
+771
+260% +$10.1K ﹤0.01% 1221
2022
Q2 		$4K Buy
297
+241
+430% +$2.24K ﹤0.01% 1716
2022
Q1 		$1K Buy
+56
New +$616 ﹤0.01% 2428

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Lindbrook Capital's KNTE Position: Q4 2022 in Review

Lindbrook Capital sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2022, closing a stake of 1,068 shares — an estimated $13K sold.

Lindbrook Capital first reported a position in KNTE in Q1 2022 and held it in 3 quarters. The position peaked at $13K in Q3 2022. 79 funds tracked by Wall St. Rank hold KNTE as of Q4 2022.

  • Lindbrook Capital reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Lindbrook Capital sold 1,068 Kinnate Biopharma Inc. Common Stock shares in Q4 2022, an estimated $13K.
  • Lindbrook Capital first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Lindbrook Capital's Kinnate Biopharma Inc. Common Stock position peaked at $13K in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2022.

Based on Lindbrook Capital's 13F filing for Q4 2022, filed 25 Jan 2023.